Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18618414 | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME | March 2024 | May 2025 | Allow | 13 | 1 | 0 | No | No |
| 18612767 | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES | March 2024 | March 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18415608 | HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3 | January 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18510412 | COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORS | November 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18453404 | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer | August 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18446032 | ANTIBODIES BINDING TO CD3 and CD19 | August 2023 | September 2024 | Allow | 14 | 0 | 1 | No | No |
| 18334582 | CD70 COMBINATION THERAPY | June 2023 | January 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18332366 | CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS | June 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18328707 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER | June 2023 | April 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18056166 | METHODS OF USING ANTI-PSGL-1 ANTIBODIES IN COMBINATION WITH JAK INHIBITORS TO TREAT T-CELL MEDIATED INFLAMMATORY DISEASES OR CANCERS | November 2022 | January 2025 | Allow | 26 | 1 | 1 | No | No |
| 17961827 | BLOOD-BASED TUMOR MUTATION BURDEN PREDICTS OVERALL SURVIVAL IN NSCLC | October 2022 | December 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17935152 | ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY | September 2022 | December 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17877020 | USE OF IMMUNE CHECKPOINT INHIBITORS IN COMBINATION WITH ANTI-AGING DRUGS IN PREPARATION OF TUMOR TREATMENT PRODUCTS | July 2022 | May 2025 | Abandon | 33 | 3 | 0 | No | No |
| 17811282 | METHODS OF TREATING CANCERS HAVING A BRCA1 AND/OR BRCA2 MUTATION(S) | July 2022 | November 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17854739 | COMBINATION OF A SUBSTANCE MODULATING TUMOR IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | June 2022 | February 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17844814 | Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses Thereof | June 2022 | February 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17728265 | USE OF IL-1BETA BINDING ANTIBODIES | April 2022 | March 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17770039 | NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF | April 2022 | May 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17610873 | DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17437179 | BIO-RESPONSIVE ANTIBODY COMPLEXES FOR ENHANCED IMMUNOTHERAPY | September 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17411158 | Treatment of Non-Small Cell Lung Cancer with EGFR Mutations | August 2021 | November 2024 | Allow | 38 | 4 | 1 | Yes | No |
| 17426443 | TREATMENT OF NEUROTOXICITY AND/OR CYTOKINE RELEASE SYNDROME | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17422265 | ANTI-BETA 1 INTEGRIN HUMANIZED ANTIBODY, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME | July 2021 | February 2025 | Allow | 43 | 1 | 0 | No | No |
| 17323844 | BISPECIFIC AND TETRAVALENT CD137 AND FAP MOLECULES FOR THE TREATMENT OF CANCER | May 2021 | August 2023 | Allow | 27 | 1 | 1 | No | No |
| 17314946 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | May 2021 | June 2025 | Allow | 49 | 4 | 0 | No | Yes |
| 17287838 | METHODS OF TREATING NSCLC COMPRISING ADMINISTERING PLATINUM DOUBLET CHEMOTHERAPY FOLLOWED BY AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY | April 2021 | December 2024 | Allow | 44 | 1 | 1 | No | No |
| 17287727 | IVIG COMPOSITION AND METHOD OF TREATMENT OF ANTIBODY DEFICIENT PATIENTS | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17284208 | THERAPEUTIC ANTIBODY FRAGMENTS, METHODS OF MAKING, AND METHODS OF USE | April 2021 | July 2024 | Allow | 39 | 1 | 0 | No | No |
| 17180492 | METHOD AND DEVICE FOR EARLY CANCER SCREENING | February 2021 | August 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 16972724 | ANTIGEN BINDING CONSTRUCTS TO CD4 | December 2020 | March 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17108771 | COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS | December 2020 | May 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17017942 | COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS | September 2020 | August 2024 | Allow | 47 | 2 | 2 | No | No |
| 16902173 | Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies | June 2020 | June 2023 | Allow | 36 | 4 | 1 | No | No |
| 16837477 | ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR TREATING TUMORS | April 2020 | May 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 16077720 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | August 2018 | November 2024 | Abandon | 60 | 7 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALSOMAIRY, SARAH ABDOALATIF.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALSOMAIRY, SARAH ABDOALATIF works in Art Unit 1646 and has examined 32 patent applications in our dataset. With an allowance rate of 59.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner ALSOMAIRY, SARAH ABDOALATIF's allowance rate of 59.4% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALSOMAIRY, SARAH ABDOALATIF receive 1.88 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ALSOMAIRY, SARAH ABDOALATIF is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.0% benefit to allowance rate for applications examined by ALSOMAIRY, SARAH ABDOALATIF. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.0% of applications are subsequently allowed. This success rate is in the 54% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.5% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.